Bristol-myers squibb company BMY.US 總覽分析
)BMY 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分較低，不過公司股利評分優異，若想穩定收息，仍可以考慮持續持有。但若僅以價值投資為目標可以減碼換股操作
BMY 近期報酬表現
-1.55%
Bristol-myers squibb company
1.31%
同產業平均
0.58%
S&P500
與 BMY 同產業的標的表現
- MIRA Mira pharmaceuticals inc價值 -趨勢 3 分波段 2 分籌碼 1 分股利 1 分查看更多
BMY 公司資訊
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its platforms comprise chemically synthesized or small molecule drugs, including protein degraders; drugs produced from biological processes, called biologics; ADCs, CAR-T cell therapies, and radiopharmaceutical therapeutics. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are also used. Biologics are typically administered through injections or by intravenous infusion. CAR-T cell therapies are administered by intravenous infusion. Its growth portfolio includes Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Opdualag, and others. Its legacy portfolio includes Eliquis, Revlimid, Pomalyst/Imnovid, Sprycel and Abraxane.